How to define remission in ankylosing spondylitis?
- 1 April 2012
- journal article
- review article
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 71 (Suppl 2) , i93-i95
Abstract
Remission can be divided into (1) clinical remission; (2) absence of objective inflammation such as a raised C-reactive protein (CRP) or active inflammation on MRI shown on a short τ inversion recovery (STIR) sequence; (3) reaching normal function; (4) prevention of (further) structural damage and (5) remission of extra-articular manifestations/associated diseases such as uveitis, psoriasis or inflammatory bowel disease (IBD).Keywords
This publication has 17 references indexed in Scilit:
- Clinical and imaging efficacy of infliximab in HLA–B27–Positive patients with magnetic resonance imaging–determined early sacroiliitisArthritis & Rheumatism, 2009
- Severity of baseline magnetic resonance imaging–evident sacroiliitis and HLA–B27 status in early inflammatory back pain predict radiographically evident ankylosing spondylitis at eight yearsArthritis & Rheumatism, 2008
- Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitisArthritis & Rheumatism, 2008
- Comparison of two different dosages of celecoxib with diclofenac for the treatment of active ankylosing spondylitis: results of a 12-week randomised, double-blind, controlled studyAnnals of the Rheumatic Diseases, 2008
- Critical appraisal of assessment of structural damage in ankylosing spondylitis: Implications for treatment outcomesArthritis & Rheumatism, 2008
- Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti–tumor necrosis factor agents infliximab and etanerceptArthritis & Rheumatism, 2005
- Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: A randomized clinical trialArthritis & Rheumatism, 2005
- Efficacy and safety of infliximab in patients with ankylosing spondylitis: Results of a randomized, placebo‐controlled trial (ASSERT)Arthritis & Rheumatism, 2005
- Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor α blockers in ankylosing spondylitisAnnals of the Rheumatic Diseases, 2004
- Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitisArthritis & Rheumatism, 2001